Antares Pharma, Inc. (Amex:AIS) today announced that total revenues for the quarter ended December 31, 2005 increased 3% to approximately $734,000 from approximately $716,000 for the same quarter in 2004. The gross margin percentage also increased in the fourth quarter of 2005 to 64% from 50% in the comparable quarter of 2004 as the mix of revenues changed and more royalties, with minimal costs, were reported in 2005. Total operating expenses decreased approximately $546,000 or 18% to $2.4 million in the fourth quarter of 2005 from $3.0 million in the same period of 2004 due to general and administrative cost controls. Total operating losses for the quarter decreased approximately $662,000 or 25% to $2.0 million from $2.6 million for the same period in 2004.
